Last reviewed · How we verify
NCT06666582
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
trial testing Paclitaxel and ramucirumab in Gastric Cancer Stage IV in 185 participants. Completed in 15 January 2024.
30 March 2023
Quick facts
| Lead sponsor | Hellenic Cooperative Oncology Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 185 |
| Start date | 1 March 2015 |
| Primary completion | 30 March 2023 |
| Estimated completion | 15 January 2024 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Paclitaxel and ramucirumab — full drug profile →
Conditions studied
- Gastric Cancer Stage IV — all drugs for Gastric Cancer Stage IV →
- Second-line Treatment — all drugs for Second-line Treatment →
- Ramucirumab Paclitaxel — all drugs for Ramucirumab Paclitaxel →
Sponsor
Hellenic Cooperative Oncology Group
Who can join
18 and older, any sex, with Gastric Cancer Stage IV or Second-line Treatment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our aim was to evaluate whether second-line treatment with paclitaxel and ramucirumab was associated with improved clinical outcomes compared to other available therapies. This study involved real-world data collection, focusing on the safety and efficacy of therapeutic combinations, administered to patients with pretreated advanced gastric cancer in the Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06666582
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer Stage IV
Currently open trials in the same condition.
- NCT05319639 — Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab · Phase 1, PHASE2 · recruiting
- NCT04592211 — Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer · Phase 1, PHASE2 · recruiting
Other Hellenic Cooperative Oncology Group trials
Trials by the same sponsor.
- NCT07528911 — Elements of Adaptive Immunity in Epithelial Ovarian Cancer · completed
- NCT06504719 — Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan · completed
- NCT04985058 — Real-world Data in Patients With Breast Cancer Treated With Abemaciclib · recruiting
- NCT04632173 — Head and Neck cancERs International cOviD-19 collabOraTion · unknown
- NCT04745377 — Responses to COVID-19 Vaccination in Patients With Cancer · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06666582 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hellenic Cooperative Oncology Group
- Last refreshed: 30 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06666582.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing